Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,280 active trials259 approved drugs3,813 evidence items
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,351 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05376423 | To Evaluate OBI-833/OBI-821 in Patients With Locally Advanced, Globo H-Positive Esophageal Cancer for Recurrence | unknown | Phase 2 | 60 | National Taiwan University HospitalOTHER | 1 | Nov 15, 2023 | clinicaltrials |
| NCT05839470 | Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer | unknown | Phase 2 | 20 | Fujian Cancer HospitalOTHER_GOV | 1 | Nov 15, 2023 | clinicaltrials |
| NCT06124001 | Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 36 | CNBG-Virogin Biotech (Shanghai) Ltd.INDUSTRY | 0 | Nov 15, 2023 | clinicaltrials |
| NCT00997009 | Study of Adding Cetuximab to Chemotherapy for the Treatment of Advanced and/or Recurrent Cervical Cancer(MITO CERV 2) | unknown | Phase 2 | 108 | National Cancer Institute, NaplesOTHER | 1 | Nov 14, 2023 | clinicaltrials |
| NCT04034459 | FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC(AIO-KRK-0116) | unknown | Phase 2 | 109 | Ludwig-Maximilians - University of MunichOTHER | 1 | Nov 14, 2023 | clinicaltrials |
| NCT04308837 | A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation | unknown | Phase 2 | 29 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Nov 14, 2023 | clinicaltrials |
| NCT02624128 | Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck(V-CHANCE) | unknown | Phase 2 | 39 | National Cancer Institute, NaplesOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT03503786 | Carboplatin, Paclitaxel With or Without Avelumab in Advanced or Recurrent Endometrial Cancer(MITO END-3) | unknown | Phase 2 | 125 | National Cancer Institute, NaplesOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT05998928 | A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy | unknown | Phase 2 | 10 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT06126237 | A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 120 | Keymed Biosciences Co.LtdINDUSTRY | 0 | Nov 13, 2023 | clinicaltrials |
| NCT06129955 | Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma | unknown | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT05311709 | Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities(SOLUCOM) | unknown | Phase 2 | 100 | Vestre Viken Hospital TrustOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT06125171 | Tucidinostat Plus Apatinib for Advanced Osteosarcoma | unknown | Phase 2 | 46 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Nov 9, 2023 | clinicaltrials |
| NCT05234658 | Study of an Artificial Human Skin Medicine for Patients With Basal Cell Carcinoma Undergoing Reconstructive Surgery | unknown | Phase 2 | 21 | Andalusian Network for Design and Translation of Advanced TherapiesOTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT05490485 | Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell Carcinoma | unknown | Phase 2 | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Nov 8, 2023 | clinicaltrials |
| NCT06123455 | Clinical Study of Taurine Combined With Sintilimab and Chemotherapy for Treatment of Advanced Gastric Cancer | unknown | Phase 2 | 60 | Tang-Du HospitalOTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT04467801 | Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy(Ipat-Lung) | unknown | Phase 2 | 60 | Jun Zhang, MD, PhDOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT05863325 | A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 80 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Nov 7, 2023 | clinicaltrials |
| NCT06118047 | Crisaborole Ointment for Skin Toxicity Induced by Cetuximab(COSTIC) | unknown | Phase 2 | 33 | Sun Yat-sen UniversityOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT06120127 | Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence(IMPROVE) | unknown | Phase 2 | 80 | Fudan UniversityOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT03088059 | Biomarker-based Study in R/M SCCHN(UPSTREAM) | unknown | Phase 2 | 340 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Nov 3, 2023 | clinicaltrials |
| NCT05094804 | A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents | unknown | Phase 1 / Phase 2 | 172 | OncoResponse, Inc.INDUSTRY | 1 | Nov 2, 2023 | clinicaltrials |
| NCT05781958 | Cadonilimab Combined With Gem/Cis as First Line Therapy in Patients With Advanced ICC | unknown | Phase 2 | 64 | Shen FengOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT06087419 | A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients | unknown | Phase 1 / Phase 2 | 42 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Nov 2, 2023 | clinicaltrials |
| NCT03742193 | Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy(PROACH) | unknown | Phase 2 | 43 | Ruijin HospitalOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT03951142 | Imaging Perfusion Restrictions From Extracellular Solid Stress - An Open-label Losartan Study(ImPRESS) | unknown | Phase 2 | 165 | Kyrre Eeg EmblemOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT06111326 | BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 83 | Biocity Biopharmaceutics Co., Ltd.INDUSTRY | 1 | Nov 1, 2023 | clinicaltrials |
| NCT06111625 | Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL | unknown | Phase 2 | 20 | Sichuan UniversityOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT04097002 | First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients. | unknown | Phase 1 / Phase 2 | 24 | Orca Therapeutics B.V.INDUSTRY | 1 | Oct 31, 2023 | clinicaltrials |
| NCT04753203 | Alpelisib and Capecitabine in Patients With PIK3CA Mutant mCRC Patients(ALCAP) | unknown | Phase 1 / Phase 2 | 65 | Korean Cancer Study GroupOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT05182931 | A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)(I-FIRST) | unknown | Phase 2 | 80 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT05785325 | RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer | unknown | Phase 2 | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT06108726 | A Study of Local Envafolimab Injection Combined With Chemotherapy in Non-small Cell Lung Cancer | unknown | Phase 2 | 16 | Northern Jiangsu People's HospitalOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT06105658 | Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML | unknown | Phase 2 | 20 | Anhui Provincial HospitalOTHER_GOV | 1 | Oct 30, 2023 | clinicaltrials |
| NCT06103279 | Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin | unknown | Phase 2 / Phase 3 | 40 | Ain Shams UniversityOTHER | 0 | Oct 26, 2023 | clinicaltrials |
| NCT04942067 | APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 108 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Oct 25, 2023 | clinicaltrials |
| NCT04964518 | A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML) | unknown | Phase 1 / Phase 2 | 24 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Oct 25, 2023 | clinicaltrials |
| NCT05466474 | PD-1 Antibody Tislelizumab Combined With Dacarbazine in the Treatment of Advanced Melanoma | unknown | Phase 2 | 40 | Henan Cancer HospitalOTHER_GOV | 1 | Oct 24, 2023 | clinicaltrials |
| NCT04277858 | Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Oropharyngeal Cancer.(NECTORS) | unknown | Phase 2 | 60 | Nader SadeghiOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT05959694 | A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . | unknown | Phase 1 / Phase 2 | 107 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06092606 | A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients | unknown | Phase 2 | 90 | Monyan Pharmaceutical (Shanghai) Co., Ltd.INDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT05229874 | Effect of CNSI vs. ICG in Lymph Node Tracing During Gastrectomy(FUTURE-01) | unknown | Phase 2 | 96 | Hebei Medical UniversityOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT06088056 | A Phase II Study of T-DXd Plus SRT in HER2-positive Breast Cancer Brain Metastases | unknown | Phase 2 | 17 | Fudan UniversityOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT06089330 | A Study of JMT101 in Patients With Metastatic Colorectal Cancer | unknown | Phase 2 | 102 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Oct 18, 2023 | clinicaltrials |
| NCT03638297 | PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer(PCOX) | unknown | Phase 2 | 29 | Sun Yat-sen UniversityOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT05290090 | ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL | unknown | Phase 2 | 31 | Zhejiang Cancer HospitalOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT04267315 | Trigger Point Injections for Post-Mastectomy Pain Syndrome | unknown | Phase 2 | 72 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT05363007 | Spleen Irradiation With Nanoliposomal Irinotecan Plus 5-FU and Leucovorin in Metastatic Pancreatic Adenocarcinoma(SINAI) | unknown | Phase 2 | 60 | National Taiwan University HospitalOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT06083701 | Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study | unknown | Phase 1 / Phase 2 | 32 | Peking Union Medical College HospitalOTHER | 1 | Oct 16, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Nov 15, 2023source: clinicaltrials